CAR T-cell therapies in clinical practice
During the Multiple Myeloma Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the current use of CAR T-cell therapies in clinical practice, with a focus on patient-specific considerations in the development of personalized treatment plans. To open, Hermann Einsele provides a presentation reviewing the latest data from trials of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) in relapsed/refractory multiple myeloma (RRMM), including the KarMMa and CARTITUDE trials. He explores criteria for the identification of patients who may benefit from CAR T-cell therapy, mechanisms of resistance to BCMA CAR T-cell therapy, and the rationale for the earlier application of CAR T-cell therapies in MM. Einsele provides a review of the toxicities associated with immunotherapies, including strategies for prevention and monitoring, management techniques for CRS and ICANS, and infection prophylaxis and management. Following his presentation, Einsele chaired a Q&A session featuring Paul Richardson, Heinz Ludwig, María-Victoria Mateos, Meral Beksaç, Elena Zamagni, and Vania Tietsche De Moraes Hungria. Discussions included the implementation of CAR T-cell therapies in earlier lines of therapy, CAR T-cell therapies in high-risk disease, maintenance after CAR T-cell therapies, and toxicities with CAR T-cell therapies and bispecifics. This educational resource is independently supported by Bristol Myers Squibb. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.